BiomEdit
Emily Bulian Helmes has a strong background in regulatory affairs and business development. Emily Bulian is currently the Vice President, Regulatory at BiomEdit since April 2022. Prior to this, they held roles at Elanco, where they served as the Senior Director, Global Regulatory Nutritional Health from April 2019 to December 2021. Before that, they worked as an Advisor, Global Regulatory Nutritional Health from 2013 to April 2019. Earlier in their career, they had a long tenure at ChemGen Corp, where they served as the Director, Regulatory Affairs & Business Development from 2005 to 2012 and from 1987 to 1997. Before joining ChemGen Corp, they worked as a Business Manager, Chemicals & Specialties at Independent Project Analysis from 1998 to 2005.
Emily Bulian Helmes has a Bachelor of Science degree in Chemistry from Tufts University. Emily Bulian also holds a Master of Business Administration (MBA) degree with a field of study in Marketing from the University of California, Berkeley, Haas School of Business.
This person is not in any offices
BiomEdit
BiomEdit is an innovation company that discovers, designs, and develops novel probiotics, microbiome derived bioactives, and engineered microbial medicines to address unmet needs in animal health. Our ambition is to create solutions to some of the most important problems in animal agriculture and food security by leveraging the potential of themicrobiome. BiomEdit’s technology is based on a unique platform that utilizes high-throughput sequencing and data analytics to rapidly discover and screen novel probiotic species and bioactive molecules. These can then be engineered to confer thermostability, enhanced production of beneficial metabolites, or expression of immune modulating proteins. These probiotics and microbially-derived compounds represent the next generation of products designed to promote animal health without the use of antibiotics.